000 | 01978 a2200553 4500 | ||
---|---|---|---|
005 | 20250516150008.0 | ||
264 | 0 | _c20130801 | |
008 | 201308s 0 0 eng d | ||
022 | _a1432-0843 | ||
024 | 7 |
_a10.1007/s00280-013-2164-3 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aTan, Antoinette R | |
245 | 0 | 0 |
_aEffects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. _h[electronic resource] |
260 |
_bCancer chemotherapy and pharmacology _cJun 2013 |
||
300 |
_a1635-43 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
650 | 0 | 4 | _aCytochrome P-450 CYP3A |
650 | 0 | 4 | _aCytochrome P-450 CYP3A Inhibitors |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 | _aDrug Interactions |
650 | 0 | 4 |
_aEsomeprazole _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIndazoles |
650 | 0 | 4 |
_aKetoconazole _xadministration & dosage |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
650 | 0 | 4 |
_aProton Pump Inhibitors _xadministration & dosage |
650 | 0 | 4 |
_aPyrimidines _xadministration & dosage |
650 | 0 | 4 |
_aSulfonamides _xadministration & dosage |
700 | 1 | _aGibbon, Darlene G | |
700 | 1 | _aStein, Mark N | |
700 | 1 | _aLindquist, Diana | |
700 | 1 | _aEdenfield, Jeffery W | |
700 | 1 | _aMartin, Julie C | |
700 | 1 | _aGregory, Charles | |
700 | 1 | _aSuttle, A Benjamin | |
700 | 1 | _aTada, Hiroomi | |
700 | 1 | _aBotbyl, Jeffrey | |
700 | 1 | _aStephenson, Joseph J | |
773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 71 _gno. 6 _gp. 1635-43 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-013-2164-3 _zAvailable from publisher's website |
999 |
_c22716932 _d22716932 |